Clin2
NCT06838143Possibly a fitRecruiting

Ilaris real-world study for periodic fevers and sJIA

Hereditary Periodic Fever SyndromesCryopyrin-associated Periodic Syndromes (CAPS)Colchicine Resistance Familial Mediterranean Fever (crFMF)TNF Receptor Associated Periodic Syndrome (TRAPS)Hyper-IgD Syndrome / Mevalonate Kinase Deficiency (HIDS/MKD)Systemic Juvenile Idiopathic Arthritis (sJIA)

Part of Blood & lymphatic, Bones, joints & muscles, Brain & nervous system, Genetic & congenital, Hormones & metabolism, Immune system & allergy, Skin clinical trials.

This study watches how people with certain periodic fever syndromes or a severe type of childhood arthritis (sJIA) do on the medicine Ilaris during their regular doctor visits. It collects information to see how well the medicine works in everyday care.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
25 people
Ages
2 years to 100 years
Study type
Observational

Who can take part

  • You must have one of these inflammatory conditions: CAPS, crFMF, TRAPS, HIDS/MKD (for adults or children 2+), or sJIA (for children 2 to 18 years old)
  • You are either already taking Ilaris (canakinumab) as part of your regular care, or you and your doctor have agreed to start it
  • You are not taking Ilaris for another autoimmune disease (like rheumatoid arthritis or lupus)
  • You are not currently in another research study that changes how your condition is treated

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07247266Recruiting· Phase 1
Testing JTE-162 for CAPS (FCAS and MWS)

This study tests an experimental drug called JTE-162 for people with certain types of CAPS (cryopyrin-associated periodic syndrome). The goal is to see if it's safe and can help control symptoms like fever, rash, and joint pain.

North York, Ontario
NCT06718049Not yet recruiting
IL-18 and IL-18BP as biomarkers for juvenile arthritis and fevers

This study looks at whether measuring certain proteins (IL-18 and IL-18BP) in the blood can help doctors tell the difference between different causes of fever in children, such as juvenile arthritis, autoinflammatory diseases, or serious infections.

Bologna, Bologna
NCT02991469Recruiting· Phase 2
Testing sarilumab for children with systemic juvenile arthritis

This trial studies sarilumab, a targeted medicine, to help reduce symptoms in children and teens with systemic juvenile idiopathic arthritis (sJIA) who have not responded enough to current treatments. You may be considered because the study looks at how well and safely repeated doses work in pediatric patients.

San Miguel de Tucumán, Tucumán Province
NCT03510442Recruiting
Study of joint illness patterns and genes in juvenile and adult diseases

This study follows people with systemic juvenile idiopathic arthritis (sJIA), adult-onset Still’s disease (AOSD), and similar conditions to learn how the illness works over time. It also collects blood and family information to study genetics and explain what causes flare-ups, which may help future care.

Bethesda, Maryland
NCT05927454Recruiting
RaDiCo Acostill study for inflammatory fevers and arthritis

This is a long-term study that collects health information and lab samples from people who have certain diagnoses of recurring (coming and going) inflammatory fevers and related joint or immune conditions. It may help researchers better understand these diseases and how they work over time.

Paris, Île-de-France Region
NCT05609630Recruiting· Phase 3
Testing two medicines for active systemic juvenile arthritis

This Phase 3 trial studies how well upadacitinib (a pill) and tocilizumab (a shot/IV medicine) improve symptoms and inflammation in children with active systemic juvenile idiopathic arthritis (sJIA). It also looks at side effects and how these medicines move through the body.

Phoenix, Arizona

Hear when a new Systemic Juvenile Idiopathic Arthritis (sJIA) trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.